Research Report

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience

Maria Kaparelou a,*, Michalis Liontos a, Pelagia Katsimbri b, Aggeliki Andrikopoulou a, Alikistis Papatheodoridi a, Anastasios Kyiazoglou c, Aristotelis Bamias c, Flora Zagouri a, Meletios Athanasios Dimopoulos a

a Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
b Rheumatology Unit, 4th Dept of Internal Medicine, ATTIKON University Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece
c 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

A R T I C L E   I N F O

Keywords:
Bevacizumab
Arthralgia
Ovarian cancer
Vascular endothelial growth factor
Targeted therapy
Joint manifestation

A B S T R A C T

Background: Joint manifestations are ill-defined adverse events that were frequently reported of bevacizumab in ovarian cancer patients. The aim of this study is to describe the incidence and severity of joint manifestations among bevacizumab treated patients as well as their relation to clinical outcomes.

Methods: Medical charts of all ovarian cancer patients that received bevacizumab from 2012 through 2017 were reviewed. Joint manifestations were staged. Kaplan-Meier Survival curves were generated; survival differences were estimated.

Results: 76 Patients diagnosed with stage III or IV ovarian cancer were included. 23 patients (30.3%) developed joint manifestations, 12 of them had Grade I, 4 Grade II and 7 Grade III. Only 3 patients developed arthritis. In 8 cases (34.8%) one joint was affected and in the remaining 15, multiple sites. Median number of bevacizumab cycles to arthralgia development was 7. 3 patients were managed with corticosteroids or methotrexate, all had grade 3 AEs. The remaining received common analgesics. Median duration of the AE was 4.8 months. 7 patients discontinued bevacizumab due to AE. In all but 3 patients AE was finally resolved. Median number of bevacizumab cycles received, frequency of treatment completion or treatment discontinuation due to disease progression did not differ significantly among patients that developed joint manifestations or not. Median PFS and median OS did not differ statistically significantly.

Conclusion: Joint manifestations are common AEs in bevacizumab treated ovarian cancer patients and led to treatment discontinuation in 9% of the patients. However, this has not adversely affected the clinical outcome of the patients. Further research is needed for the appropriate management of these patients.

1. Introduction

Ovarian cancer is the fourth most common cause of cancer related deaths in women (Perren et al., 2011). Standard treatment for women with advanced disease is debulking surgery followed by platinum – based chemotherapy, most commonly paclitaxel and carboplatin (Perren et al., 2011; Burger et al., 2011). The monoclonal anti-VEGF antibody bevacizumab was the first targeted therapy approved for use in advanced ovarian cancer (Perren et al., 2011; Burger et al., 2011). The addition of the antiangiogenic agent bevacizumab to carboplatin plus paclitaxel, followed by bevacizumab alone provided benefit to the time until disease progression and currently is a treatment option in patients with newly diagnosed advanced ovarian cancer (Colombo et al., 2019; Karam et al., 2017; Tewari et al., 2019; Oza et al., 2015).

Bevacizumab is a recombinant humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF). Bevacizumab inhibits VEGF signaling by blocking the binding of VEGF to its receptors and reduces tumor growth by suppressing angiogenesis in tumor tissues (Goodheart et al., 2005; Hollingsworth et al., 1995; Paley et al., 1997). Vascular endothelial growth factor (VEGF) and angiogenesis are important promoters of ovarian cancer progression (Goodheart et al., 2005; Hollingsworth et al., 1995; Paley et al., 1997; Gasparini et al., 1996; Alvarez et al., 1999). Both correlate directly with the extent of disease and inversely with progression-free survival.

* Corresponding author.
E-mail address: kapareloum@gmail.com (M. Kaparelou).

https://doi.org/10.1016/j.gore.2022.100953
Received 15 January 2022; Received in revised form 24 February 2022; Accepted 26 February 2022
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(Goodheart et al., 2005; Hollingsworth et al., 1995; Paley et al., 1997) and overall survival (Hollingsworth et al., 1995; Gasparini et al., 1996; Alvarez et al., 1999; Shen et al., 2000; Duncan et al., 2008), often independently of known prognostic factors (Gasparini et al., 1996; Shen et al., 2000; Duncan et al., 2008).

Clinical development and real-world clinical practice have demonstrated the adverse events of bevacizumab. Some of them are considered as class effects and are directly related to drug’s mechanism of action including gastrointestinal perforation, hypertension, proteinuria and thrombo-embolism. These adverse events are well characterized in the various neoplasms that bevacizumab has been approved and specific guidance for their management as well as joint manifestations. Joint manifestations are ill-defined adverse events (AE) that were frequently reported in the registrational trials of bevacizumab in ovarian cancer patients (Aghajanian et al., 2015). Arthralgia is a non-inflammatory pain of joints. Many cancer patients suffer from this problem during their cancer treatment. Vascular endothelial growth factor (VEGF) plays a major role in the pathophysiology of joint pain and therefore, anti-VEGF therapies are in particular associated with this complication. Arthralgia is defined as joint pain, stiffness or aching in the joints (Langenberg et al., 2011; Garcia et al., 2008).

Under this perspective, we hypothesized that joint manifestations are underreported adverse events in ovarian cancer patients receiving bevacizumab in the frontline setting and their occurrence could affect treatment and survival due to either premature treatment discontinuation or in the contrary due to serving as an indicator of treatment efficacy by creating an on-target off-tumor adverse event. Therefore, we undertook a retrospective analysis of patients treated in our institution with bevacizumab for advanced ovarian cancer. Our study aimed at describing the frequency and severity of joint manifestations in this population and identify possible implications in their survival.

2. Patients and Methods

Medical charts of patients that received bevacizumab as part of their first line treatment in our institution from 2012 through 2017 were reviewed. Patients with a diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III/IV epithelial ovarian cancer, fallopian tube cancer/primary peritoneal cancer based on the findings at initial debulking surgery who were scheduled to receive first-line chemotherapy, or patients with Stage III/IV epithelial ovarian cancer, fallopian tube cancer/primary peritoneal cancer by cytological diagnosis or histological and imaging diagnosis who had undergone interval debulking surgery after neoadjuvant chemotherapy and were scheduled to receive postoperative chemotherapy were included. The study has been approved by the Institutional Ethics Committee and was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. All patients provided written informed consent for their participation. Demographic, clinicopathological characteristics, data regarding bevacizumab administration, adverse events and their management as well as survival data were recorded.

2.1. Statistical analysis

Continuous variables were summarized with the use of descriptive statistical measures [median and percentiles (25th, 75th)] and categorical variables were displayed as frequency tables (N, %). Number of bevacizumab cycles included also those cycles that the medication was co-administered with chemotherapy. Joint manifestations, more specifically Joint Pain (Arthralgia) and Arthritis were assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.1. Overall Survival (OS) was defined as the time between the start of chemotherapy and the date of death from any cause. Progression-free Survival (PFS) was defined as the time between the start of chemotherapy and the date of progression. Alive patients were censored at the date of last contact. Kaplan-Meier estimates were used to describe and visualize the effect of categorical variables on OS and PFS. Log-rank tests were used to explore the prognostic value of categorical variables on clinical outcomes. The association of these factors with PFS and OS was assessed through HRs and their 95% confidence intervals estimated from univariate Cox proportional hazards models. All statistical analyses were performed using the SPSS software.

3. Results

3.1. Study population

Between 2012 and 2017, 76 women were included in our analysis. The clinicopathological characteristics of these patients are presented in Table 1. In details, the median age was 56.15 years and all patients had an ECOG performance status of 0 or 1. The majority of patients had FIGO stage IIIc (82.9% — 63 patients) or stage IV disease (10.5% — 8 patients). The rest patients had stage IIIa (1.3% — 1 patient) and 5.3% (4 patients) had IIib disease. 86.8% (66 patients) had a serous histologic type, 3.9% (3 patients) had endometrioid histologic type, 3.9% (3 patients) clear cell and 5.3% (4 patients) had adenocarcinoma NOS histologic type. From these patients 72.4% (55 patients) underwent Primary debulking surgery whereas 27.6% (21 patients) were operated after neoadjuvant treatment (Interval debulking Surgery). Concerning BRCA1 mutation 13.2% (10 out of 76) of the patients were BRCA1/2 mutant, 40.8% (31 patients) were BRCA1/2 wild type and there was 46.1% (35 patients) that were not tested.

3.2. Bevacizumab-related study manifestations

Twenty-three patients (30.3%) developed joint manifestations, 12 (52.2%) of them had Grade 1, 4 (17.4%) had Grade II and 7 (30.4) had Grade III symptoms. In our cohort, only 4 out of the 23 patients developed joint manifestations while receiving bevacizumab along with chemotherapy (17.4%). In the remaining cases, the adverse event appeared at least one cycle after chemotherapy completion, allowing for a clear association with bevacizumab administration. In all cases adverse event was deemed related to treatment with bevacizumab. All patients that developed arthritis had Grade 3 severity. In eight cases (34.8%) one joint was affected and in the remaining 15 patients (65.2%), multiple sites were affected. Three of them were managed with corticosteroids or methotrexate. All of them had grade 3 AEs. The remaining patients received common analgesics (26.1% — 6

| Table 1 | Clinicopathological characteristics of the patients. |
|---|---|
| Characteristics | Median, n (%) |
| Stage | |
| Ic | 2 | 2.6% |
| IIa | 1 | 13% |
| IIib | 4 | 5.3% |
| IIIc | 61 | 80.3% |
| IV | 8 | 10.5% |
| Histology | |
| Serous | 66 | 86.8% |
| Endometrioid | 3 | 3.9% |
| Clear cell | 3 | 3.9% |
| Adenocarcinoma NOS | 4 | 5.3% |
| Surgery | |
| Primary debulking | 55 | 72.4% |
| Interval debulking | 21 | 27.6% |
| BRCA1/2 mutations | |
| Presence | 10 | 13.2% |
| Absence | 31 | 40.8% |
| Unknown | 35 | 46.1% |
An adverse event (AE) but could compromise quality of life and impair data (Perren et al., 2011; Burger et al., 2011). More severe of them patients. Administration of bevacizumab has been related to various adverse events as are joint manifestations have been reported in a significant percentage of patients with ovarian cancer treated with bevacizumab (Aghajanian et al., 2015). Joint manifestations are ill-defined although mild in the majority of patients. However, in the era of targeted therapies, long lasting mild adverse events could also affect compliance with treatment and lead to permanent drug discontinuation. In addition, mild drug-related adverse events as are joint manifestations have been reported in a significant number of patients during frontline treatment of these patients may have obscured the reporting of joint manifestation that were attributed to bevacizumab. Also, survival – both progression free and overall – was similar between patients with joint manifestations and those without symptoms. Therefore, it is likely that development of arthralgia during bevacizumab treatment do not impair survival.

On the other hand, joint manifestations induced by bevacizumab could be an on-target, off-tumour effect of the drug. Analogous cases have been suggested for several targeted agents. Hypertension is a common adverse event for all anti-VEGF medications. Hypertension induced by VEGF-TKIs has been associated with favourable outcome in patients with metastatic kidney cancer. Vascular endothelial growth factor (VEGF) is implicated in the pathophysiology of pain and joint pain in particular (Nagai et al., 2014). More specifically, VEGF exerts neuroprotective effects (Sondell et al., 2000) and VEGF inhibition may cause degeneration of motor neurons (Ootsubo et al., 2001) and painful sensory neuropathy by inhibiting the VEGFR2 (Verheyen et al., 2012; Beazley-Long et al., 2013). Both VEGFR tyrosine kinase inhibitors and anti-VEGF antibodies affect negatively dorsal root ganglion neurons in and HDAC6-dependent manner (Verheyen et al., 2012). Due to the neuroprotective effects of VEGF, it is postulated that long term exposure to anti-VEGF agents may also affect other types of neurons as well. Indeed, severe optic neuropathies have been recorded in glioblastoma patients treated with bevacizumab (Sherman et al., 2009). It should be noted though, that antiangiogenic treatment may have protective effect in the pain related to pre-existing osteoarthritis by a different mechanism. It is considered that increased VEGF levels in the synovial fluid are related to painful osteoarthritis and disease development (Bonnet and Walsh, 2005). Angiogenesis induced by chronic inflammation in osteoarthritis may mediate neo-innervation that contributes to joint pain experience (Mayer et al., 1999). Thus, bevacizumab has been tested successfully in preclinical models as a treatment of osteoarthritis. Under this perspective, the exact mechanism that bevacizumab may induce joint manifestations in ovarian cancer patients remain vague and it cannot be truly considered an off-tumour effect of the drug.

Finally, in our cohort of patients, joint manifestations were reported at a median number of seven administrations of bevacizumab. This implies that for the majority of the patients the onset of the adverse event was detected after frontline chemotherapy completion. This as well as the median duration of the symptoms are in accordance with previous published study (Ventriglia et al., 2021). A possible explanation could be that joint manifestations are a late onset adverse event of bevacizumab. On the other hand, bone, joint and muscle pains are frequently encountered during chemotherapy administration and are usually attributed by treating physicians to cytotoxic drugs or possible G-CSF administration. This underlies the possibility that early onset joint manifestation possibly attributed to bevacizumab could be underreported during a retrospective collection of data. This is confirmed also by a prospective analysis of joint pain during bevacizumab treatment in various neoplasms. Monotherapy of bevacizumab for more than 5 months was significantly associated with the appearance of this adverse event in this study (Vaulèon et al., 2021).

Our study has several limitations. First of all, it is subjected to all biases attributed to the retrospective collection of data. Also, it is a single center analysis. However, this ensures the homogeneity of treatment in these patients in a reference center for gynecological malignancies. Also, the number of patients may be limited, but it is analogous to those published in previous corresponding trials. Finally, co-administration of chemotherapy with bevacizumab during the initial phase of frontline treatment of these patients may have obscured reporting of joint manifestation that were attributed to bevacizumab treatment during this period. Our study has strengths too. We evaluated

### Table 2
Characteristics of joint manifestations in the cohort of patients.

| Characteristics | n | (%) |
|-----------------|---|-----|
| Presence of joint manifestations | | |
| No | 53 | 69.7% |
| Yes | 23 | 30.3% |
| Type of joint manifestations | | |
| Arthralgia | 20 | 87% |
| Arthritis | 3 | 13% |
| Adverse event Grading | | |
| Grade 1 | 12 | 52.2% |
| Grade 2 | 4 | 17.4% |
| Grade 3 | 7 | 30.4% |
| Location of adverse event | | |
| One joint | 8 | 34.8% |
| Multiple joints | 15 | 65.2% |
| Adverse event management | | |
| No treatment | 6 | 26.1% |
| Common analgesics | 6 | 26.1% |
| NSAIDs | 8 | 34.8% |
| Steroids/methotrexate | 3 | 13.0% |
| Adverse event outcome | | |
| Recovered | 19 | 82.6% |
| Ongoing | 4 | 17.4% |
all types of joint manifestations that could be attributed to bevacizumab administration, according to CTCAE criteria for the grading of adverse events. In addition, we have a long follow-up of the patients allowing for the association of these adverse events not only with PFS but with OS as well. Finally, we have described in detail the clinical course of these events allowing for proper management of these patients in the future.

In conclusions, our study confirms that joint manifestations are a common problem among women receiving bevacizumab maintenance treatment for ovarian cancer. We have shown that proper management leads to treatment discontinuation to only a limited number of cases. It is also reassuring that treatment interruption or premature discontinuation does not adversely affect survival in these patients. Physicians are aware of these low intensity and quite bothersome adverse events of bevacizumab and studies like ours provide information to guide therapeutic decisions in the future.

Fig. 1. A. Joint manifestations and completion of treatment. B. Joint manifestations and presence of BRCA1/2 mutations.

|                      | Joint manifestations |               |
|----------------------|----------------------|---------------|
|                      | No                  | Yes           |
| Events (N/%)         | 40/53 (75.5%)       | 14/23 (61.9%) |
| mPFS                 | 22.7                | 25.4          |

Fig. 2. A. Joint manifestations and progression free survival (PFS). B. Joint manifestations and overall survival (OS).

CRediT authorship contribution statement

Maria Kaparelou: Methodology, Resources, Data curation, Writing – original draft. Michalis Liontos: Methodology, Data curation, Writing – original draft. Pelagia Katsimbri: Methodology, Resources, Data curation, Writing – review & editing. Aggeliki Andrikopoulou: Data curation, Writing – review & editing. Alikistis Papatheodoridi: Writing – review & editing. Aristotelis Kyriazoglou: Data curation, Writing – review & editing. Flora Zagouri: Resources, Supervision, Writing – review & editing. Meletios Athanasios Dimopoulos: Resources, Supervision, Project administration, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Aghajanian, C., Goff, B., Nycum, L.R., Wang, Y.V., Husain, A., Blank, S.V., 2015. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol. 139 (1), 10–16.

Alvarez, A.A., Krigman, H.R., Whitaker, R.S., Dodge, R.K., Rodriguez, G.C., 1999. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res. 5, 587–591.

Beazley-Long, N., Hua, J., Jehle, T., et al., 2013. VEGF-A165B is an endogenous neuroprotective splice isoform of Vascular Endothelial Growth Factor A in vivo and in vitro. Am J Pathol 183 (3), 918–929.

Bonnet, C.S., Walsh, D.A., 2005. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44 (1), 7–16.

Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., Bonnet, C.S., Walsh, D.A., 2005. Osteoarthritis, angiogenesis and inflammation. J Clin Pathol 58 (7), 672–675.

Colombo, N., Seno, G., do Bois, A., et al., 2019. ESMO-ESGO consensus recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 30, 3030–3035.

Garzia, A.A., Hirir, H., Fleming, G., Yang, D., Tsao-Wei, D.D., Roman, L., Grosben, S., Swenson, S., Markland, F., Gandara, D., Scudder, S., Morgan, R., Chen, H., Lenz, H.-J., Oza, A.M., 2008. Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J. Clin. Oncol. 26 (1), 76–82.

Gasparini, G., Bonoldi, E., Viale, G., Verderio, P., Boracchi, P., Panizzoni, G.A., Radosii, U., Di Bacco, A., Guglielm, R.B., Bevilacqua, F., 1996. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer 69 (3), 205–211.

Goodheart, M.J., Ritchie, J.M., Rose, S.L., Deen, S., Liu, D.T.Y., Spindlove, I., Durrant, L.G., 2008. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin. Cancer Res. 14 (10), 3030–3035.

Hollingsworth, H.C., Kohn, E.C., Steinberg, S.M., Rothenberg, M.L., Merino, M.J., 1995. Goodheart, M.J., Ritchie, J.M., Rose, S.L., Fruehauf, J.P., De Young, B.R., Buller, R.E., Langenberg, M.H.G., Witteveen, P.O., Roodhart, J., Lolkema, M.P., Verheul, H.M.W., Mayer, D.J., Mao, J., Holt, J., Price, D.D., 2001. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28 (2), 131–138.

Oza, A.M., Cook, A.D., Pfisterer, J., Embleton, A., Ledermann, J.A., Pujeaud-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Park-Simon, T.W., Rustin, G., Joly, F., Mirza, M.R., Plante, M., Quinn, M., Poveda, A., Jayson, G.G., Stark, D., Swart, A.M., Farrelly, L., Kaplan, R., Parmar, M.K.B., Perren, T.J., 2015. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16 (8), 928–936.

Paley, P.J., Staskus, K.A., Gehbhard, K., Mohranaj, D., Twiggs, L.B., Carson, L.F., Ramakrishnan, S., 1997. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80 (1), 96–106.

Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujeaud-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Kurzeder, C., Bois, A.D., Sehouli, J., Kimmig, R., Stahl, A., Collinson, F., Esteban, P., Gourley, C., Lorhslary, A., Selle, F., Mirza, M.R., Lemisen, A., Plante, M., Stark, D.K., Qian, W., Parmar, M.K.B., Oza, A.M., 2011. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365 (26), 2473–2483.

Parmar, M.K.B., Oza, A.M., 2011. A phase 3 trial of bevacizumab in ovarian cancer. JCO.2011.39.15_suppl.5501, 5501-5501.

Shen, G.H., Ghazizadeh, M., Kawazome, O., Shimizu, H., Jin, E., Araki, T., Sagisaki, Y., 2000. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 82 (4), 196–203.

Sherman, J.H., Aregawi, D.G., Lai, A., Fathallah-Shaykh, H.M., Bierman, P.J., Linsky, K., Lerner, J.M., Newman, S.A., Schiff, D., 2009. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73 (22), 1924–1926.

Sondell, M., Sundler, F., Kanje, M., 2000. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur. J. Neurosci. 12 (12), 4243–4254.

Tewari, K.S., Burger, R.A., Enserro, D., et al., 2019. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317–2328.

Vauloup, E., Behal, H., Lebellet, I., Desbarboux, R., Baldacci, S., Simon, N., Pannier, D., Vieillard, M.-H., Turpin, A., 2021. Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHALGIA study. CancerChemoTher Pharmacol. 87 (4), 533–541.

Ventriglia, J., Paciolla, I., Pisano, C., Tamburo, R., Coccure, S.C., Di Napoli, M., Attademo, L., Arriazi, L., Spina, A., Russo, D., Califano, D., Losito, N.S., Setola, S.V., Franzese, E., De Vita, F., Ordutia, M., Pignata, S., 2021. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. J. Gynecol. Cancer 11 (1), 110–115.

Verheyen, A., Peerzad, E., Nuydens, R., et al., 2012. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 135, 2629–2641.